Sunepitron

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sunepitron
Sunepitron.png
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 148408-65-5
PubChem (CID) 9799246
ChemSpider 7975011
UNII 2GT50C8U60 YesY
KEGG D02569
ChEMBL CHEMBL380369
Chemical and physical data
Formula C17H23N5O2
Molar mass 329.40 g/mol
3D model (Jmol) Interactive image

Sunepitron (CP-93,393) is a combined 5-HT1A receptor agonist and α2-adrenergic receptor antagonist.[1][2] It was previously under development by Pfizer for the treatment of depression and anxiety.[3] It made it to phase III clinical trials before being discontinued.[2][3]

Synthesis[edit]

Sunepitron synthesis: G.N. Bright, K.A. Desai, U.S. Patent 5,122,525 (1992).

The synthesis starts by conversion of the pyridine dicarboxylic acid (1) to its acid chloride; rxn with MeOH then affords the ester (2). Catalytic hydrogenation serves to reduce the pyridine ring to a piperidine of undefined stereochemistry (3). Alkylation of this intermediate with chloroacetonitrile affords (4). Treatment of that intermediate with Raney nickel reduces the cyano group to the corresponding primary amine; this product then undergoes an internal ester-amine interchange to yield the cyclized lactam (5). LAH serves to reduce the lactam to an amine; the ester on the other ring is reduced to a carbinol in the process, affording the aminoalcohol (7). The basic function is next alkylated with 2-chloropyrimidine (7). Rxn of the alcoholin (8) with MsCl leads to the mesylate; that group is next displaced by sodium azide (9); the azide group is next reduced to the primary amine. Resolution of this product as its mandelate salt then yields (10) as a single enantiomer. Rxn of that product with succinic anhydride converts the pendant amine to a succinimide, affording the anxiolytic agent sunepitron (1).

See also[edit]

References[edit]

  1. ^ Goodnick PJ (July 1999). "Psychopharmacology of depression in the next millennium". CNS Spectrums. 4 (7): 21–35. PMID 18438295. 
  2. ^ a b Stahl, S. M. (2000). Essential psychopharmacology: neuroscientific basis and practical application. Cambridge, UK: Cambridge University Press. ISBN 0-521-64615-4. 
  3. ^ a b Kaplan, Eliot F.; Turkington, Carol (2001). Making the antidepressant decision: how to choose the right treatment option for you and your loved ones. Chicago, Ill: Contemporary Books. ISBN 0-7373-0417-0. 
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sunepitron&oldid=745247351"